• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    January 13, 2022 - FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species

    1/13/22 10:26:13 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZTS alert in real time by email
    For Immediate Release:
    January 13, 2022

    Today, the U.S. Food and Drug Administration approved Solensia (frunevetmab injection), the first treatment for the control of pain associated with osteoarthritis in cats and the first monoclonal antibody (mAb) new animal drug approved by the FDA for use in any animal species. 

    Frunevetmab, the active ingredient in Solensia, is a cat-specific monoclonal antibody (a type of protein) designed to recognize and attach to a protein called nerve growth factor (NGF) that is involved in the regulation of pain. When frunevetmab binds to NGF, it prevents the pain signal from reaching the brain.

    “Treatment options for cats with osteoarthritis are very limited. Advancements in modern veterinary medicine have been instrumental in extending the lives of many animals, including cats. But with longer lives come chronic diseases, such as osteoarthritis,” said Steven M. Solomon, M.P.H., D.V.M., director of the FDA’s Center for Veterinary Medicine. “Today’s approval marks the first treatment option to help provide relief to cats that are suffering from this condition and may significantly improve their quality of life. We also hope that today’s approval of the first monoclonal antibody by the FDA for any animal species will expand research and development of other monoclonal antibody products to treat animal diseases.” 

    Osteoarthritis is a degenerative condition of the joints in which the normal cartilage cushion in the joints breaks down. Eventually, the bones in the joint rub against each other, causing pain, decreased joint movement, and sometimes the formation of bone spurs or other changes in and around the joint. Osteoarthritis continues to get worse over time; however, Solensia can help manage the pain associated with the condition to improve the cat’s quality of life.

    Solensia is available only by prescription from a licensed veterinarian because professional expertise is required to properly diagnose pain associated with osteoarthritis in cats, administer the injection and monitor the safe use of the product, including treatment of any adverse reactions. Solensia is given through subcutaneous (under the skin) injection once a month and is dosed based on the weight of the animal. 

    Because of the difficulty in assessing chronic pain levels in cats, the FDA looked at whether the overall evidence supported the conclusion that Solensia was effective in controlling pain associated with osteoarthritis in cats. The effectiveness of Solensia was evaluated in two effectiveness studies using three clinical assessments that measured different aspects of pain associated with osteoarthritis in cats. 

    The two clinical trials were both masked, randomized, controlled field studies involving client-owned cats with clinical signs of osteoarthritis. The cats’ veterinarians assessed the cats based on orthopedic examinations before and after treatment. The owners of the cats provided baseline scores of their cats’ levels of impairment doing certain activities (such as jumping onto furniture, using the litter box or grooming), compared to the cats’ level of ability before they developed osteoarthritis. The owners then assessed their cats’ response after receiving treatment. Overall, the cats in the treatment group had better assessment scores than those in the control group.

    The most common side effects seen in cats treated with Solensia included vomiting, diarrhea, injection site pain, scabbing on the head and neck, dermatitis and pruritus (itchy skin). These effects were relatively mild and did not require cessation of treatment. 

    Veterinarians should advise owners about the possible adverse events and side effects before using the drug. The FDA encourages cat owners to work with their veterinary team to report any adverse events or side effects potentially related to the use of any drug, including Solensia.

    The FDA granted approval of Solensia to Zoetis Inc.
     

    Related Information

    Related Information
    • NADA 141-546 FOI Summary (fda.gov)

    ###

    Boilerplate

    The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.


    Inquiries

    Media:
    Veronika Pfaeffle
    301-310-2576
    Consumer:
    888-INFO-FDA

    Get the next $ZTS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZTS

    DatePrice TargetRatingAnalyst
    7/17/2025$155.00Outperform → Market Perform
    Leerink Partners
    6/18/2025$160.00Buy → Hold
    Stifel
    12/2/2024$215.00Outperform
    Leerink Partners
    7/25/2024$220.00Buy
    BTIG Research
    1/12/2024$195.00 → $215.00Buy
    Stifel
    12/19/2023$230.00Buy
    Jefferies
    12/7/2023$237.00Outperform
    Exane BNP Paribas
    9/6/2023$230.00Buy
    HSBC Securities
    More analyst ratings

    $ZTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zoetis Announces Third Quarter 2025 Results

    Reports Revenue of $2.4 Billion, Growing 1%, and Net Income of $721 Million, or $1.63 per Diluted Share, Increasing 6% and 9%, Respectively, on a Reported Basis for Third Quarter 2025 Delivers 4% Organic Operational Growth in Revenue and 9% Organic Operational Growth in Adjusted Net Income for Third Quarter 2025 Reports Adjusted Net Income of $754 Million, or Adjusted Diluted EPS of $1.70, for Third Quarter 2025 Revises Full Year 2025 Revenue Guidance to $9.400 - $9.475 Billion with Organic Operational Revenue Growth of 5.5% to 6.5% Based on Broader Macro Trends and the Operational Environment Narrows Full Year 2025 Guidance for Organic Operational Growth in Adjusted Net Income

    11/4/25 7:00:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Announces Retirement of Rob Polzer at the End of 2025 and the Appointment of Kevin Esch as President of Research & Development for World Leader in Animal Health Beginning in 2026

    Dr. Rob Polzer to Retire at the End of the Year After 10-Year Distinguished Career of Advancing Veterinary Medicine and Innovation Zoetis Inc. (NYSE:ZTS) today announced that following a 10-year distinguished career dedicated to advancing veterinary medicine and innovation, Rob Polzer, Ph.D., Executive Vice President and President, Research and Development, has made the personal decision to retire at the end of 2025. After a planful succession process, Zoetis has appointed Kevin Esch, D.V.M, M.P.H., Ph.D., Dipl. ACVP (anatomic) to succeed Dr. Polzer in this role, effective January 1, 2026. Dr. Esch currently serves as Senior Vice President of Global Therapeutics at Zoetis and joined Zoe

    11/3/25 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Receives European Commission Marketing Authorization for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats

    Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Portela® (relfovetmab), making it the first monoclonal antibody (mAb) therapy with a three-month dosing interval approved for the alleviation of pain associated with osteoarthritis (OA) in cats. Designed to provide three months of OA pain relief with a single injection, Portela targets anti-nerve growth factor (NGF), which is a key mediator of OA pain and inflammation. In September of this year, the Committee for Veterinary Medicinal Products (CVMP) recommended granting marketing authorization based on a positive benefit-risk balance of the safety and efficacy data submitted. In a

    10/29/25 8:30:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    January 13, 2022 - FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species

    For Immediate Release: January 13, 2022 Today, the U.S. Food and Drug Administration approved Solensia (frunevetmab injection), the first treatment for the control of pain associated with osteoarthritis in cats and the first monoclonal antibody (mAb) new animal drug approved by the FDA for use in any animal species.  Frunevetmab, the active ingredient in Solensia, is a cat-specific monoclonal antibody (a type o

    1/13/22 10:26:13 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Leadership Updates

    Live Leadership Updates

    View All

    Zoetis Announces Retirement of Rob Polzer at the End of 2025 and the Appointment of Kevin Esch as President of Research & Development for World Leader in Animal Health Beginning in 2026

    Dr. Rob Polzer to Retire at the End of the Year After 10-Year Distinguished Career of Advancing Veterinary Medicine and Innovation Zoetis Inc. (NYSE:ZTS) today announced that following a 10-year distinguished career dedicated to advancing veterinary medicine and innovation, Rob Polzer, Ph.D., Executive Vice President and President, Research and Development, has made the personal decision to retire at the end of 2025. After a planful succession process, Zoetis has appointed Kevin Esch, D.V.M, M.P.H., Ph.D., Dipl. ACVP (anatomic) to succeed Dr. Polzer in this role, effective January 1, 2026. Dr. Esch currently serves as Senior Vice President of Global Therapeutics at Zoetis and joined Zoe

    11/3/25 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Appoints Stephanie Tilenius to its Board of Directors

    Health entrepreneur brings her digital and artificial intelligence (AI) experience to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the appointment of Stephanie Tilenius to its Board of Directors, effective as of December 1, 2025. Ms. Tilenius brings extensive experience in technology-forward, digital health organizations to the Zoetis Board. Ms. Tilenius is a serial entrepreneur and has founded several healthcare companies, including most recently a stealth company in the longevity AI space. Previously, she founded Vida Health, Inc., a leading B2B chronic care platform focusing on diabetes and obesity, and scaled it nationally for Fortune 500 companies, large payers and healthcar

    10/28/25 8:30:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dr. Mark Stetter Elected to Zoetis Board of Directors

    Dean of the University of California, Davis School of Veterinary Medicine brings extensive and valuable experience in animal health to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the election of Dr. Mark Stetter to its Board of Directors, effective as of the company's annual shareholder meeting on May 21, 2025. Dr. Stetter brings extensive experience in veterinary medicine and animal health, including as Dean of the University of California, Davis School of Veterinary Medicine, to the Zoetis Board. His career in animal health includes pets, livestock, exotic animals, research and wildlife. He will serve on the Board's Quality and Innovation Committee. "Dr. Stetter brings invaluab

    5/22/25 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Financials

    Live finance-specific insights

    View All

    Zoetis Announces Third Quarter 2025 Results

    Reports Revenue of $2.4 Billion, Growing 1%, and Net Income of $721 Million, or $1.63 per Diluted Share, Increasing 6% and 9%, Respectively, on a Reported Basis for Third Quarter 2025 Delivers 4% Organic Operational Growth in Revenue and 9% Organic Operational Growth in Adjusted Net Income for Third Quarter 2025 Reports Adjusted Net Income of $754 Million, or Adjusted Diluted EPS of $1.70, for Third Quarter 2025 Revises Full Year 2025 Revenue Guidance to $9.400 - $9.475 Billion with Organic Operational Revenue Growth of 5.5% to 6.5% Based on Broader Macro Trends and the Operational Environment Narrows Full Year 2025 Guidance for Organic Operational Growth in Adjusted Net Income

    11/4/25 7:00:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Declares Fourth Quarter 2025 Dividend

    The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.50 per share for the fourth quarter of 2025. The dividend will be paid on Tuesday, December 2, 2025, to all holders of record of the Company's common stock as of the close of business on Friday, October 31, 2025. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide -- from veterinarians and pet owners to livestock producers. T

    10/9/25 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis to Host Webcast and Conference Call on Third Quarter 2025 Financial Results

    Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, November 4, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review third quarter 2025 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Pre-registration for the webcast is available beginning today. A replay of the webcast will be made available on November 4, 2025. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular p

    9/23/25 8:30:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

    SC 13G/A - Zoetis Inc. (0001555280) (Subject)

    2/13/24 5:17:36 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

    SC 13G/A - Zoetis Inc. (0001555280) (Subject)

    1/26/24 11:49:41 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

    SC 13G/A - Zoetis Inc. (0001555280) (Subject)

    2/9/23 11:37:19 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Executive Vice President Fuller Julie

    4 - Zoetis Inc. (0001555280) (Issuer)

    10/14/25 4:27:52 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Executive Vice President Polzer Robert J

    4 - Zoetis Inc. (0001555280) (Issuer)

    10/14/25 4:27:59 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Joseph Wetteny

    4 - Zoetis Inc. (0001555280) (Issuer)

    10/14/25 4:27:47 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    SEC Filings

    View All

    SEC Form 10-Q filed by Zoetis Inc.

    10-Q - Zoetis Inc. (0001555280) (Filer)

    11/4/25 3:02:59 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Zoetis Inc. (0001555280) (Filer)

    11/4/25 7:06:23 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Zoetis Inc. (0001555280) (Filer)

    10/28/25 8:33:44 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Zoetis downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Zoetis from Outperform to Market Perform and set a new price target of $155.00

    7/17/25 8:01:13 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis downgraded by Stifel with a new price target

    Stifel downgraded Zoetis from Buy to Hold and set a new price target of $160.00

    6/18/25 7:45:54 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Zoetis with a new price target

    Leerink Partners initiated coverage of Zoetis with a rating of Outperform and set a new price target of $215.00

    12/2/24 7:04:18 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care